Kura Oncology Inc. | Key People and Executives
Troy E. Wilson
Chairman, President & Chief Executive Officer
Steven H. Stein
Independent Director
Thomas R. Malley
Independent Director
Faheem Hasnain
Independent Director
Robert E. Hoffman
Independent Director
Troy E. Wilson
Chairman, President & Chief Executive Officer
John Farnam
Chief Operating Officer
Marc Edward Grasso
Chief Financial Officer & Chief Business Officer
Catherine Scholz
Vice President-Clinical Development
Antonio Gualberto
Chief Medical Officer & Head-Development
Yi Liu
Chief Scientific Officer
Blake Tomkinson
Vice President-Clinical Development
Bridget A. Martell
Vice President-Clinical Development
Pingda Ren
Senior VP-Chemistry & Pharmaceutical Sciences
Pete de Spain
VP-Investor Relations & Corporate Communications
Annette North
Senior Vice President & General Counsel
Steven H. Stein
Independent Director
Thomas R. Malley
Independent Director
Faheem Hasnain
Independent Director
Robert E. Hoffman
Independent Director
| Address |
3033 Science Park Road
San Diego California 92121
United States
|
|
Employees
|
- |
| Website |
http://www.kuraoncology.com |
| Updated |
07/08/2019 |
| Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. |
